The use of pimecrolimus cream 1% in the treatment of facial psoriasis

Aim. To evaluate the efficacy of pimecrolimus cream 1% in patients with facial psoriasis. Methods. In this open study, 40 patients of both sexes (27 males and 13 females) aged between 18 and 75 years (mean age: 48.3 years) with psoriasis vulgaris affecting also the face (PASI ≤12) have been treated with pimecrolimus cream 1%. The drug has been applied to the facial lesions twice daily for 2 months. Results. Upon completion of treatment, the complete resolution of the lesions has been documented in 42.5% of cases (17 patients), and an improvement in all symptoms of erythema, desquamation and infiltration in 52.5% of cases (21 patients). Only 1 patient interrupted the treatment due to intolerance to the drug. Conclusions. In our study pimecrolimus cream 1% has shown a high level of efficacy and good tolerability in the majority of cases treated, revealing itself to be a valid therapeutic option in the treatment of facial psoriasis.